IL1B and cryopyrin-associated periodic syndrome: Lastly, rilonacept is a soluble IL-1 trap that binds IL-1α and IL-1β; it has been approved for the treatment of CAPS (Hoffman et al., 2012) and has demonstrated safety and efficacy in other inflammatory disorders (Krause et al., 2012).